Clinical trial
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic…
NCT00351975 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00351975 |
|---|---|
| Title | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases |
| Official title | A Phase I Study of PXD101 in Combination With Azacitidine (5-Aza) for Advanced Hematologic Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22), CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16, 16)(p13.1, q22), Adult Acute Myeloid Leukemia With t(8, 21)(q22, RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9 and 25 more |
| Intervention type | Drug, Other |
| Interventions | Belinostat, Azacitidine, Laboratory Biomarker Analysis |
| Enrollment | 56 |
| Start date | Jun 1, 2006 |
| Primary completion | Mar 1, 2013 |
| Completion | Mar 1, 2013 |
| First posted | Jul 14, 2006 |
| Last update posted | Dec 23, 2014 |
| Countries | Canada, New Zealand, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: